Abstract
Background: Programmed cell death 1 (PD-1) inhibitors have changed the landscape of management of advanced malignancies. However, they are often associated with cutaneous adverse effects that may prevent patients from completing treatment. Common adverse effects include morbilliform and psoriasiform rash, bullous pemphigoid-like eruptions, and dyspigmentation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
